A surprising modification lowers the lipid binding affinity of a membrane trafficking protein
Proteins undergo nonenzymatic modification by reacting with various molecules. For example, cysteine residues react with the alkylating reagent iodoacetamide, and amino groups react with certain carbonyl compounds including succinimidyl esters.
Nonspecific protein modifications in human tissues also are associated with a number of diseases; for example, most of the long-term consequences of diabetes arise from a damaging series of reactions involving blood glucose (an aldehyde) forming covalent bonds to amino groups on various proteins.
Physicians calculate average blood glucose concentrations in diabetic patients by measuring the levels of the glycated protein hemoglobin A1C, a modified form of the red blood cell protein with glucose attached to the N-terminal amino group of the beta-chain. Because such nonenzymatic reactions are typically irreversible, they result in damaged proteins that can lose function and must be removed via proteolytic degradation, a cell’s normal process of breaking down proteins and recycling amino acids.
In a lab, when reactions occur on foreign proteins during bacterial expression, researchers need to design a purification strategy that removes the modified protein. Many modifications do not show up in sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis and thus are easily overlooked.
In a recent study, we identified an endogenous protein modification occurring on a cluster of lysine residues that are central to lipid binding properties in the vesicle trafficking protein granuphilin, or Slp-4. This protein binds reversibly to plasma membranes via a conserved region called a C2 domain, which binds membranes independently of calcium via a large positively charged surface that interacts with negatively charged lipids. At the center of this surface is a cluster of lysines that has a high affinity for the plasma membrane lipid phosphatidylinositol-(4,5)-bisphosphate, or PIP2. We also found that two of these conserved lysines are susceptible to modification by the endogenous bacterial compound phosphogluconolactone, an intermediate in the pentose phosphate pathway. Not surprisingly, the modified protein binds much less strongly to PIP2 lipids than the unmodified protein.
Researchers previously have reported phosphogluconoylation of bacterially expressed proteins but only as a modification on an N-terminal His-tag, never on an internal lysine sidechain. The modified protein manifested as an early-eluting peak during cation-exchange purification, and we identified the site of modification using mass spectrometry following trypsin digestion.

lysine cluster (red circle) embedded in a large electropositive surface (blue oval) containing many basic
residues (blue sticks). A single exposed hydrophobic residue (gray sticks) also contributes to membrane affinity.
Researchers also already knew that certain PIP2-binding C2 domains must be purified via cation exchange in order to obtain reproducible results. Our results suggest that the purpose of this step is not only to remove nucleic acid contaminants but also to separate out this endogenous bacterial modification, which can be a significant percentage of the total protein.
Why is this observation important to lipid biochemistry? Some of the most reactive carbonyl compounds in mammalian cells are aldehydes derived from polyunsaturated fatty acids, or PUFAs. These compounds are downstream products that arise from reaction of PUFAs with reactive oxygen species such as peroxide and superoxide, which become more abundant during oxidative stress and inflammation. PUFAs are especially abundant as acyl chains in phosphoinositide lipids such as PIP2.
Therefore, our observation of reactivity in this PIP2-binding lysine cluster raises several questions: How reactive is this lysine cluster toward endogenous lipid aldehydes in mammalian cells? Does lysine modification affect membrane trafficking? Are there other proteins with lysine clusters that possess similar reactivity?
A serendipitous observation of protein modification during bacterial expression has opened the door to questions at the heart of protein chemistry and membrane biology.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

RA patient blood reveals joint innerworkings
Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

Defeating deletions and duplications
Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.